Abstract
Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 397-407 |
| Number of pages | 11 |
| Journal | Canadian Veterinary Journal |
| Volume | 59 |
| Issue number | 4 |
| State | Published - Apr 1 2018 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- veterinary(all)
Cite this
Update on the use of trilostane in dogs. / Lemetayer, Julie Denise; Blois, Shauna.
In: Canadian Veterinary Journal, Vol. 59, No. 4, 01.04.2018, p. 397-407.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Update on the use of trilostane in dogs
AU - Lemetayer, Julie Denise
AU - Blois, Shauna
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.
AB - Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=85048220216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048220216&partnerID=8YFLogxK
M3 - Review article
C2 - 29606727
AN - SCOPUS:85048220216
VL - 59
SP - 397
EP - 407
JO - Canadian Veterinary Journal
JF - Canadian Veterinary Journal
SN - 0008-5286
IS - 4
ER -